Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sorich

Showing results (21-30 of 216) with videos related to

Pageof 22
Sort By:
BMJ (Clinical Research Ed.)|March 20, 2024
Quality and safety of artificial intelligence generated health informationMichael J Sorich, Bradley D Menz, Ashley M Hopkins
Clinical Pharmacology and Therapeutics|May 15, 2013
Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogeneticsM J Sorich, T M Polasek, M D Wiese
Thrombosis and Haemostasis|May 4, 2012
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleedingMichael J Sorich, Thomas M Polasek, Michael D Wiese
Plos One|September 10, 2013
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroupsMichael J Sorich, Michael Coory, Brita A K Pekarsky
Anti-Cancer Drugs|January 7, 1999
Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancerT Safra, S Jeffers, J Sorich, et al.
Pharmaceuticals (Basel, Switzerland)|April 30, 2021
Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib DosingWarit Ruanglertboon, Michael J Sorich, Ashley M Hopkins, et al.
The Oncologist|April 5, 2021
Regarding the Article by Rugo et alSarah Badaoui, Andrew Rowland, Michael J Sorich, et al.
International Journal of Clinical Oncology|May 18, 2020
Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patientsWarit Ruanglertboon, Michael J Sorich, Andrew Rowland, et al.
European Journal of Clinical Pharmacology|May 5, 2017
Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio: could a drug-induced toxicity be regulating exposure to the offending agent?Andrew Rowland, Angela Rowland, Michael J Sorich, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 19, 2021
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literatureAlia Fahmy, Ashley M Hopkins, Michael J Sorich, et al.
Pageof 22

Showing results (21-30 of 216) with videos related to

Sort By:
Pageof 22
BMJ (Clinical Research Ed.)|March 20, 2024
Quality and safety of artificial intelligence generated health informationMichael J Sorich, Bradley D Menz, Ashley M Hopkins
Clinical Pharmacology and Therapeutics|May 15, 2013
Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogeneticsM J Sorich, T M Polasek, M D Wiese
Thrombosis and Haemostasis|May 4, 2012
Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleedingMichael J Sorich, Thomas M Polasek, Michael D Wiese
Plos One|September 10, 2013
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroupsMichael J Sorich, Michael Coory, Brita A K Pekarsky
Anti-Cancer Drugs|January 7, 1999
Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancerT Safra, S Jeffers, J Sorich, et al.
Pharmaceuticals (Basel, Switzerland)|April 30, 2021
Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib DosingWarit Ruanglertboon, Michael J Sorich, Ashley M Hopkins, et al.
The Oncologist|April 5, 2021
Regarding the Article by Rugo et alSarah Badaoui, Andrew Rowland, Michael J Sorich, et al.
International Journal of Clinical Oncology|May 18, 2020
Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patientsWarit Ruanglertboon, Michael J Sorich, Andrew Rowland, et al.
European Journal of Clinical Pharmacology|May 5, 2017
Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio: could a drug-induced toxicity be regulating exposure to the offending agent?Andrew Rowland, Angela Rowland, Michael J Sorich, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 19, 2021
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literatureAlia Fahmy, Ashley M Hopkins, Michael J Sorich, et al.
Pageof 22